GRAIL (NASDAQ:GRAL) Stock Rating Upgraded by TD Cowen

GRAIL (NASDAQ:GRAL) was upgraded by investment analysts at TD Cowen from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Marketbeat reports. The firm currently has a $65.00 price target on the stock. TD Cowen’s price objective suggests a potential upside of 34.10% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. Canaccord Genuity Group reduced their target price on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a report on Friday, February 20th. Morgan Stanley lowered their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Thursday, January 22nd. Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research note on Friday, February 20th. Finally, Guggenheim increased their target price on shares of GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $82.00.

GRAIL Trading Up 0.1%

Shares of NASDAQ:GRAL opened at $48.47 on Wednesday. The company has a market capitalization of $1.99 billion, a PE ratio of -4.34 and a beta of 5.18. GRAIL has a 12-month low of $20.44 and a 12-month high of $118.84. The business’s fifty day simple moving average is $80.65 and its 200-day simple moving average is $78.10.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. GRAIL had a negative return on equity of 17.11% and a negative net margin of 277.46%.The firm had revenue of $43.60 million during the quarter, compared to analysts’ expectations of $43.33 million. Research analysts predict that GRAIL will post -15.15 EPS for the current year.

Insider Buying and Selling at GRAIL

In other news, President Joshua J. Ofman sold 2,937 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $47.89, for a total transaction of $140,652.93. Following the sale, the president owned 432,881 shares in the company, valued at approximately $20,730,671.09. The trade was a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Ragusa sold 7,461 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $47.89, for a total transaction of $357,307.29. Following the transaction, the chief executive officer owned 642,084 shares in the company, valued at approximately $30,749,402.76. This trade represents a 1.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 79,294 shares of company stock worth $3,955,224. 1.85% of the stock is owned by insiders.

Institutional Trading of GRAIL

Several large investors have recently bought and sold shares of GRAL. N.E.W. Advisory Services LLC acquired a new position in GRAIL during the 4th quarter valued at approximately $26,000. Comerica Bank lifted its stake in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of GRAIL during the fourth quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in shares of GRAIL during the fourth quarter valued at $31,000. Finally, Intesa Sanpaolo S.p.A. acquired a new position in shares of GRAIL in the 4th quarter valued at $44,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.